🔗 Share this article

The recently developed medications for gonorrhoea in many years are being viewed as a "major milestone" in the fight against increasingly resistant strains of the pathogen, according to scientists.

An International Challenge

The sexually transmitted infection are escalating worldwide, with estimates suggesting in excess of 82 million new cases each year. Particularly high rates are reported in Africa and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune advancement in the reality of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce available drugs currently available.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The WHO has designated it as a "high-priority threat". Recent surveillance revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Gain Authorization

Zoliflodacin, also known as Nuzolvence, was cleared by the US FDA in mid-December for combating gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Scientists believe that focused deployment of this new drug will help slow the spread of drug resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, gained clearance in the same week. This medication, which is employed against urinary tract infections, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment stemmed from a innovative non-profit model for medication research. The charitable organization GARDP partnered with the pharmaceutical company Innoviva to develop it.

“This authorization marks a significant shift in the treatment of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Clinical Trial Results and Global Access

According to findings published in a prominent scientific publication, the new drug eradicated over nine in ten of cases of the STI. This places it at an comparable level with the typical regimen, which involves a dual-drug approach. The study included over 900 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, the non-profit has the authority to register and commercialise the drug in numerous low-income and middle-income countries.

Medical professionals directly involved have expressed positive views. The availability of a single-dose, oral treatment like this is seen as a "critical tool" for managing the epidemic. This is viewed as crucial to reduce the burden of the disease for patients and to halt the transmission of untreatable gonorrhoea globally.